U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis
- PMID: 40347952
- DOI: 10.1016/S2468-1253(25)00046-9
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis
Conflict of interest statement
All authors are supported by the National Institute for Health and Care Research Cambridge Biomedical Research Centre (NIHR203312). NMN receives payment or honoraria for lectures from AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Janssen, Pfizer, Pharmacosmos, and Takeda; receives financial support for attending meetings and travel from Dr Falk Pharma, Janssen, Pharmacosmos, and Tillotts Pharma AG; and receives fees for advisory board membership from AbbVie and Bristol Myers Squibb. MP receives personal fees from J&J Innovative Medicine and Takeda and receives grants from AstraZeneca, Celltrion, Galapagos, Gilead, Pfizer, and Eli Lilly. TR receives personal fees from AbbVie, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Novartis, Numab, J&J Innovative Medicine, Pfizer, Roche, Takeda, UCB, and XAP therapeutics; receives grants from AbbVie; and receives fees for data monitoring board membership from UCB.
Comment on
-
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.Lancet Gastroenterol Hepatol. 2025 Jun;10(6):507-519. doi: 10.1016/S2468-1253(25)00017-2. Lancet Gastroenterol Hepatol. 2025. PMID: 40347957 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
